Literature DB >> 33275672

Optimizing the management of chronic pain in sickle cell disease.

Ifeyinwa Osunkwo1, Hazel F O'Connor1, Elna Saah2.   

Abstract

Chronic pain in sickle cell disease (SCD) refers to pain present on most days lasting over six months. It can start during childhood and the prevalence increases with age. By adulthood, over 55% of patients experience pain on over 50% of days; 29% reporting pain on 95% of days. The true prevalence of chronic pain in SCD is likely underappreciated as it is mostly managed at home. Patients with chronic pain and SCD frequently seek acute care for exacerbation of underlying chronic pain difficult to distinguish from their usual acute vaso-occlusive crises. When treating chronic pain in SCD, the challenge is distinguishing between non-SCD related etiologies versus chronic pain resulting from SCD pathophysiological processes. This distinction is important to delineate as it will drive appropriate management strategies. Chronic pain in SCD has profound consequences for the patient; is often associated with comorbid psychiatric illnesses (depression and anxiety), not dissimilar from other chronic pain syndromes. They may also experience challenges with sleep hygiene, various somatic symptoms, and chronic fatigue that impair quality of life. How best to treat chronic pain in SCD is not definitively established. Both acute and chronic pain in SCD is typically treated with opioids. Emerging data suggests that chronic opioid therapy (COT) is a suboptimal treatment strategy for chronic pain. This review will discuss the complexity of managing chronic pain in SCD; pain that may be dependent or independent of the underlying SCD diagnosis. We will also describe alternative treatment approaches to high-dose COT.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 33275672      PMCID: PMC7727591          DOI: 10.1182/hematology.2020000143

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  52 in total

Review 1.  Opioid therapy for chronic pain.

Authors:  Jane C Ballantyne; Jianren Mao
Journal:  N Engl J Med       Date:  2003-11-13       Impact factor: 91.245

2.  Weak and Winded.

Authors:  Ikjae Lee; Jeremey B Walker; Kenkichi Nozaki; Lisa L Willett
Journal:  N Engl J Med       Date:  2019-07-04       Impact factor: 91.245

Review 3.  Early insights into the neurobiology of pain in sickle cell disease: A systematic review of the literature.

Authors:  Amanda M Brandow; Rebecca A Farley; Julie A Panepinto
Journal:  Pediatr Blood Cancer       Date:  2015-05-13       Impact factor: 3.167

4.  Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic Pain?

Authors:  Miriam O Ezenwa; Robert E Molokie; Zaijie Jim Wang; Yingwei Yao; Marie L Suarez; Cherese Pullum; Judith M Schlaeger; Roger B Fillingim; Diana J Wilkie
Journal:  Pain Pract       Date:  2015-01-12       Impact factor: 3.183

Review 5.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

Review 6.  Haemoglobinopathies and the rheumatologist.

Authors:  Michael Hughes; Qasim Akram; David C Rees; Anthony Kenneth Peter Jones
Journal:  Rheumatology (Oxford)       Date:  2016-03-27       Impact factor: 7.580

7.  Severe Vaso-Occlusive Episodes Associated with Use of Systemic Corticosteroids in Patients with Sickle Cell Disease.

Authors:  Deepika S Darbari; Ros S Fasano; Caterina P Minniti; Oswald O Castro; Victor R Gordeuk; James G Taylor; Jeffre Y Rehm
Journal:  J Natl Med Assoc       Date:  2008-08       Impact factor: 1.798

Review 8.  Central sensitization: a generator of pain hypersensitivity by central neural plasticity.

Authors:  Alban Latremoliere; Clifford J Woolf
Journal:  J Pain       Date:  2009-09       Impact factor: 5.820

Review 9.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

Review 10.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

View more
  4 in total

1.  Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.

Authors:  Melissa Cregan; Latika Puri; Guolian Kang; Doralina Anghelescu
Journal:  Pediatr Blood Cancer       Date:  2022-02-11       Impact factor: 3.167

2.  Sickle cell bone disease and response to intravenous bisphosphonates in children.

Authors:  C Grimbly; P Diaz Escagedo; J L Jaremko; A Bruce; N Alos; M E Robinson; V N Konji; M Page; M Scharke; E Simpson; Y D Pastore; R Girgis; R T Alexander; L M Ward
Journal:  Osteoporos Int       Date:  2022-07-29       Impact factor: 5.071

3.  Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease.

Authors:  Kate M Johnson; Boshen Jiao; M A Bender; Scott D Ramsey; Beth Devine; Anirban Basu
Journal:  PLoS One       Date:  2022-04-28       Impact factor: 3.752

4.  Health-Related Quality of Life Among Patients With Sickle Cell Disease in an Adult Hematology Clinic in a Tertiary Hospital in Lagos, Nigeria.

Authors:  Lemchukwu Amaeshi; Olufunto O Kalejaiye; Chibuzor F Ogamba; Folasade Adelekan Popoola; Yusuf A Adelabu; Chibuikem A Ikwuegbuenyi; Ijeoma B Nwankwo; Oluwademilade Adeniran; Michael Imeh; Michael O Kehinde
Journal:  Cureus       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.